Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

immunotherapy

  • You have access
    Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors
    Shadi A. Esfahani, Carolina De Aguiar Ferreira, Priska Summer, Umar Mahmood and Pedram Heidari
    Journal of Nuclear Medicine April 6, 2023, jnumed.123.265391; DOI: https://doi.org/10.2967/jnumed.123.265391
  • Open Access
    Imaging of Activated T Cells
    Mohammad O. Sako and Benjamin M. Larimer
    Journal of Nuclear Medicine January 1, 2023, 64 (1) 30-33; DOI: https://doi.org/10.2967/jnumed.122.264097
  • Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of <sup>89</sup>Zr-Labeled Anti-PD-L1 Antibody Formats
    You have access
    Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats
    Alizée Bouleau, Hervé Nozach, Steven Dubois, Dimitri Kereselidze, Céline Chevaleyre, Cheng-I Wang, Michael J. Evans, Vincent Lebon, Bernard Maillère and Charles Truillet
    Journal of Nuclear Medicine August 1, 2022, 63 (8) 1259-1265; DOI: https://doi.org/10.2967/jnumed.121.262967
  • PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
    You have access
    PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
    Jasper Smit, Frank J. Borm, Anna-Larissa N. Niemeijer, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Daniela E. Oprea-Lager, Danielle J. Vugts, Guus A.M.S. van Dongen, Berlinda J. de Wit-van der Veen, Erik Thunnissen, Egbert F. Smit and Adrianus J. de Langen
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 686-693; DOI: https://doi.org/10.2967/jnumed.121.262473
  • CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
    You have access
    CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
    Michael D. Farwell, Raymond F. Gamache, Hasan Babazada, Matthew D. Hellmann, James J. Harding, Ron Korn, Alessandro Mascioni, William Le, Ian Wilson, Michael S. Gordon, Anna M. Wu, Gary A. Ulaner, Jedd D. Wolchok, Michael A. Postow and Neeta Pandit-Taskar
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 720-726; DOI: https://doi.org/10.2967/jnumed.121.262485
  • 
    Study of <sup>89</sup>Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer
    You have access
    Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer
    Anna-Larissa N. Niemeijer, Daniela E. Oprea-Lager, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Berlinda J. de Wit-van der Veen, Idris Bahce, Daniëlle J. Vugts, Guus A.M.S. van Dongen, Erik Thunnissen, Egbert F. Smit and Adrianus J. de Langen
    Journal of Nuclear Medicine March 1, 2022, 63 (3) 362-367; DOI: https://doi.org/10.2967/jnumed.121.261926
  • Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma
    You have access
    Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma
    Justin Ferdinandus, Wolfgang P. Fendler, Katharina Lueckerath, Christoph Berliner, Sabine Kurzidem, Eva Hadaschik, Joachim Klode, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Ken Herrmann, Juergen C. Becker and Selma Ugurel
    Journal of Nuclear Medicine March 1, 2022, 63 (3) 396-398; DOI: https://doi.org/10.2967/jnumed.121.262344
  • Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    You have access
    Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482
  • Immune-Checkpoint Blockade Enhances <sup>225</sup>Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
    You have access
    Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
    Johannes Czernin, Kyle Current, Christine E. Mona, Lea Nyiranshuti, Firas Hikmat, Caius G. Radu and Katharina Lückerath
    Journal of Nuclear Medicine February 1, 2021, 62 (2) 228-231; DOI: https://doi.org/10.2967/jnumed.120.246041
  • You have access
    Development and Evaluation of Interleukin-2–Derived Radiotracers for PET Imaging of T Cells in Mice
    Elly L. van der Veen, Frans V. Suurs, Frederik Cleeren, Guy Bormans, Philip H. Elsinga, Geke A.P. Hospers, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries, Erik F.J. de Vries and Inês F. Antunes
    Journal of Nuclear Medicine September 1, 2020, 61 (9) 1355-1360; DOI: https://doi.org/10.2967/jnumed.119.238782

Pages

  • Next
  • 1
  • 2
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire